TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29049469
Drug: Extended-release naltrexone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone, 380 mg, administered intramuscularly every fourth week for 12 weeks
Study: 29049469
Drug: Buprenorphine-naloxone, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone, daily oral flexible dose 4 to 24 mg/d
Study: 26081066
Drug: NT‐proBNP concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP concentrations in women who developed CVD (81 ng/l [50 to 147])
Study: 29944164
Drug: High SPF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High SPF sunscreen applied at 1.3 mg/cm2
Study: 29944164
Drug: High SPF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High SPF sunscreen applied at 2.0 mg/cm2
Study: 29944164
Drug: High SPF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High SPF sunscreen applied at 0.75 mg/cm2
Study: 24956119
Drug: MBL-HCV1 treatment
Normalized name: MBL-HCV1
DrugBank: MBL-HCV1 (DB17776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBL-HCV1 treatment
Study: 15670539
Drug: Trimetazidine plus
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine plus sildenafil (sildenafil 100 mg 1 hour before sexual intercourse, trimetazidine 20 mg 3 times a day)
Study: 15670539
Drug: Nitrates (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates (20 mg 3 times a day)
Study: 12075057
Drug: Fumagillin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumagillin (60 mg per day orally for two weeks)
Study: 2245418
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation training before chemotherapy
Study: 31732149
Drug: Xhance® 186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xhance® 186 μg
Study: 31732149
Drug: Xhance® 372
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xhance® 372 μg
Study: 31732149
Drug: Flonase® 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flonase® 400 μg
Study: 31732149
Drug: Flovent® HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flovent® HFA 440 μg
Study: 23243239
Drug: BD supplemented
Normalized name: BD-111
DrugBank: BD-111 (DB18247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD supplemented with 2.5 mg of AFB(1)/kg of feed and 0.5% HSCAS
Study: 23243239
Drug: BD supplemented
Normalized name: BD-111
DrugBank: BD-111 (DB18247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD supplemented with 2.5 mg of AFB(1)/kg of feed
Study: 20628180
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 250 mg given thrice weekly
Study: 19841338
Drug: Prednisolone for
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone for 2 weeks (monotherapy)
Study: 19841338
Drug: Prednisolone for
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone for 2 weeks plus Ginkgo biloba for 4 weeks (combination therapy)
Study: 17075269
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline 5-8 mg/kg (dry syrup) or 100-200 mg (tablet) twice daily
Study: 11230586
Drug: No cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cooling (rectal temperature = 37.0 +/- 0.2 degrees C, n = 15)
Study: 11230586
Drug: Minimally cooled
Normalized name: INSERTER,MINIMED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally cooled (rectal temperature 36.5 degrees C to 36 degrees C, n = 6)
Study: 11230586
Drug: Mildly cooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly cooled (rectal temperature 35.9 degrees C to 35.5 degrees C, n = 6)
Study: 11230586
Drug: Mildly cooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly cooled (rectal temperature 35 +/- 0.5 degrees C, n = 6)
Study: 11230586
Drug: Mildly cooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly cooled (rectal temperature 34.5 +/- 0.5 degrees C, n = 7)
Study: 2535298
Drug: Sufentanil, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil, 5 micrograms/kg, IV with succinylcholine, 1 mg/kg, IV
Study: 2535298
Drug: Etomidate, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate, 0.4 mg/kg, IV with succinylcholine, 1 mg/kg, IV
Study: 1095310
Drug: Clotrimazole therapy
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole therapy
Study: 30595354
Drug: Fluvoxamine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (250 mg daily) plus MPH-ER (36 mg daily)
Study: 30595354
Drug: Fluvoxamine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (250 mg daily) plus placebo
Study: 26509366
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g/kg/d during 7 days)
Study: 23073950
Drug: High-dose multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multivitamin supplementation (daily oral supplements of vitamin B complex, vitamin C, and vitamin E at high levels)
Study: 23073950
Drug: Standard-dose multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose multivitamin supplementation (daily oral supplements of vitamin B complex, vitamin C, and vitamin E at standard levels)
Study: 23073950
Drug: High-dose multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multivitamin supplementation
Study: 23073950
Drug: Standard-dose multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose multivitamin supplementation
Study: 21708060
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 micrograms, once daily for 14 days
Study: 15934992
Drug: IV magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV magnesium (0.2 mg Mg per mL acid citrate dextrose‐A)
Study: 12425542
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Lactobacillus spp. and bifidobacteria
Study: 10075273
Drug: Delavirdine in
Normalized name: Product containing delavirdine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine in combination with zidovudine
Study: 10075273
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with zidovudine
Study: 2024973
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg) administered as a 1-h infusion
Study: 2024973
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg) administered as an oral tablet
Study: 2024973
Drug: Oral dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosage form of ofloxacin
Study: 6344900
Drug: M&B 22,948
Approvals — FDA: no, EMA: no, PMDA: no
Description: M&B 22,948 (10 mg)
Study: 30402473
Drug: Zearalenone (ZEA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zearalenone (ZEA) 400 μg/kg.b.w
Study: 30402473
Drug: Zearalenone (ZEA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zearalenone (ZEA) 800 μg/kg.b.w
Study: 30402473
Drug: Zearalenone (ZEA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zearalenone (ZEA) 1600 μg/kg.b.w
Study: 26823611
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol (approximately 0.065% peak breath alcohol concentration)
Study: 22492127
Drug: Interferon beta‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1b (IFNβ‐1b) 250 µg
Study: 19747410
Drug: Fermented dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented dairy product containing Lactobacillus casei DN-114001 (200 g/d)
Study: 10472396
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention including information on doping, discussions on nutritional supplements, drug simulating role play, and self-medication information.
Study: 8598548
Drug: Kunitz trypsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kunitz trypsin inhibitor
Study: 8598548
Drug: Bowman‐Birk inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowman‐Birk inhibitor
Study: 26016936
Drug: Alternative Perfusion
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative Perfusion Solution (APS)
Study: 24039213
Drug: Sunglasses worn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunglasses worn during daytime in addition to topical aqueous nasal budesonide and loratadine
Study: 24039213
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous nasal budesonide and loratadine
Study: 17851462
Drug: Protein hydrolysates
Normalized name: protein hydrolysates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein hydrolysates (pea, rice, soy, gluten, whey, egg) with 0.2 g hydrolysate per kg body weight and 0.2 g maltodextrin per kg body weight
Study: 17823625
Drug: Both pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both pioglitazone and atorvastatin
Study: 15064633
Drug: Cineole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cineole (two 100‐mg capsules three times daily)
Study: 12692603
Drug: Etoposide (E)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (E) at 800 mg/m²
Study: 12692603
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) at 910 mg/m²
Study: 10073771
Drug: Heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuit (n = 15)
Study: 10073771
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Heparin-coated and Uncoated circuits)
Study: 31221225
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine and conventional acupuncture
Study: 31221225
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine and mind-regulating acupuncture
Study: 26932738
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg/day for 6 months)
Study: 24236828
Drug: Otelixizumab (3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otelixizumab (3.1 mg over 8 days)
Study: 22300416
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation (including a photo file, demonstration of equipment using a role-modelling approach, and a tour)
Study: 22300416
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation
Study: 20367660
Drug: Ablation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation of residual potentials as add-on therapy to circumferential pulmonary vein ablation (CPVA) + pulmonary vein electrical isolation (PVI), n = 49
Study: 10498160
Drug: Long-term diuretic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term diuretic therapy
Study: 10498160
Drug: No diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diuretic therapy (Control)
Study: 6238991
Drug: Independent of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent of treatment
Study: 30761790
Drug: NefraDoz (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NefraDoz (1 capsule three times daily for one month)
Study: 30761790
Drug: Standard antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibacterial therapy (control group)
Study: 26216648
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (6000 mg day(-1) of fish oil)
Study: 26216648
Drug: Control (6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (6000 mg day(-1) of soybean oil)
Study: 25135060
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.1 g/kg/d)
Study: 23816952
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 17.5% CO2
Study: 23816952
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% CO2
Study: 18354390
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 0% CO2 (control)
Study: 16097710
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vardenafil every other day for 7 weeks after the intervention
Study: 7500239
Drug: ePTFE interproximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePTFE interproximal membranes in combination with decalcified freeze‐dried bone (DFDBA)
Study: 2878134
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 5 mg in 5 ml of water
Study: 3174151
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine 150 micrograms in 5 ml of saline
Study: 2878134
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine 0.3 mg in 5 ml of saline
Study: 29326420
Drug: Insulin to
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin to glucose ratios at 20 °C
Study: 22051332
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion (VE) with normal saline (0.25 ml/kg/min for 60 min)
Study: 19194157
Drug: Midazolam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (20 and 40 ng/ml)
Study: 19194157
Drug: Propofol (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.45 and 0.9 microg/ml)
Study: 19194157
Drug: Dexmedetomidine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.25 and 0.4 ng/ml)
Study: 19194157
Drug: Thiopental (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (1.5 and 3 microg/ml)
Study: 15070633
Drug: Three days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three days of oral amoxicillin 31‐54 mg/kg/day in three divided doses
Study: 15070633
Drug: Five days
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five days of oral amoxicillin 31‐54 mg/kg/day in three divided doses
Study: 9651060
Drug: Conventionally and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally and digitally subtracted aortic arch injection angiograms
Study: 9651060
Drug: Intravenous digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous digital subtraction angiograms
Study: 8062314
Drug: carteolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: carteolol (15 mg/d)
Study: 8062314
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 mg/d)
Study: 3190508
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid (52, 156, and 260 mmol/l)
Study: 24919603
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine with stepwise addition of up to three insulin glulisine injections (G + 3)
Study: 24919603
Drug: Twice-daily premixed
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily premixed 70/30 insulin protamine-aspart/aspart (PM-2)
Study: 24919603
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine with up to one insulin glulisine injection (G + 1)
Study: 20109213
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg PO once daily for 5 days, repeated every 8 weeks for a total of six courses
Study: 410230
Drug: 2% disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% disodium cromoglycate (DSCG) nasal spray
Study: 24839145
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for overweight, Class I, and Class II obese women
Study: 21225104
Drug: Dipyrone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (15 mg/kg)
Study: 17535290
Drug: ANALOGUE (optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANALOGUE (optimized analogue therapy; lispro/glargine)
Study: 17535290
Drug: CSII (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII (continuous subcutaneous insulin infusion therapy; lispro)
Study: 17535290
Drug: EDUCATION (re-education
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDUCATION (re-education with relaxation of blood glucose targets on existing conventional insulin regimen)
Study: 15471655
Drug: Radiotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy only (not pre-treated with chemotherapy)
Study: 11598580
Drug: Intracanal corticosteroid-antibiotic
Normalized name: antibiotics in combination with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracanal corticosteroid-antibiotic compound
Study: 9649455
Drug: Oral beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beclomethasone dipropionate (8 mg/day) plus prednisone (1 mg.kg‐1.day‐1)
Study: 9649455
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules plus prednisone (1 mg.kg‐1.day‐1)
Study: 7979170
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C intake of 20 mg/kg or more
Study: 7979170
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C intake above 20 mg/kg/day
Study: 7979170
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C intake of 8 mg/kg/day
Study: 3899082
Drug: Fenoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.2 mg)
Study: 2898368
Drug: Salbutamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (2 x 0.1 mg)
Study: 2898368
Drug: Terbutaline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (2 x 0.25 mg)
Study: 2898368
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (maximal mean plasma concentration 14.9 +/- 2.2 mg l-1) after placebo inhalation
Study: 2898368
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of theophylline and fenoterol
Study: 27411333
Drug: Remifentanil 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2.0 ng/ml
Study: 27411333
Drug: Remifentanil 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 3.0 ng/ml
Study: 27411333
Drug: Remifentanil 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 4.0 ng/ml
Study: 22487920
Drug: Local EMLA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local EMLA cream preoperatively (Group I, N=15)
Study: 22487920
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative preparation (Group II, N=15)
Study: 20500126
Drug: Caffeine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (80 mg, 3x/day for 6 days followed by a challenge dose of 250 mg)
Study: 16219950
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of orbital irradiation and systemic steroids (SRT group)
Study: 16219950
Drug: Systemic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids alone (ST group)
Study: 12153596
Drug: Dexamethasone (Dex)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (Dex) 6.5 mg/m2
Study: 12153596
Drug: Prednisolone (Pred)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (Pred) 40 mg/m2
Study: 7628186
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prednisone
Study: 2699147
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of five markers (CEA, SCC, TPA, CA 50, ferritin)
Study: 15293490
Drug: Balance training
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance training and vestibular rehabilitation in group sessions twice a week for six weeks
Study: 11430325
Drug: Indomethacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1 mg/kg body weight)
Study: 8504634
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x 5 g of creatine plus 1 g of glucose/day)
Study: 27779482
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of alprazolam orally one hour before the procedure
Study: 25404102
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (200 µg daily for 8 weeks, then 200 µg on alternate days for 16 weeks)
Study: 25404102
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray (control)
Study: 20083626
Drug: Pulsed infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed infusions of levosimendan (6 h administration at 0.2 microg/kg/min every 2 weeks)
Study: 20083626
Drug: Pulsed infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed infusions of levosimendan
Study: 12151930
Drug: NOx.5 l
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOx.5 l (oxygen-nitrous oxide, MFA after 10 min high fresh gas flow)
Study: 12151930
Drug: Ox.5 l
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ox.5 l (oxygen, MFA)